RxSight (RXST) Insider Tammenoms Bakker Juliet Buys 37,037 Shares
Several insiders at RxSight, Inc. picked up shares on June 17, 2026, adding to their stakes in the medical technology company.
Reviewed by automated data checks against the source filing. How we make and check alerts
Tammenoms Bakker Juliet bought 37,037 shares of RxSight, Inc. ($RXST) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RXST is up 15.7% after 1 week, up 20.9% after 1 month and down 1.7% to date (from the $4.59 close on Jun 17, 2026).
RXST
RxSight, Inc.
Key Points
- Several insiders at RxSight, Inc. purchased shares on June 17, 2026, adding to their stakes as the stock traded near its 52-week low.
- RxSight shares trade around $4.73, well below their 50-day moving average of $6.09 and closer to the bottom of their 52-week range.
- Wall Street firms hold mixed views on the stock, with Needham keeping a buy rating and an $11.00 price target.
Get $RXST trade alerts by text
We text you when insiders, Congress or big funds trade $RXST. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated RxSight, Inc. alert may contain errors. Disclosures
RxSight Insiders Buy Company Shares
On June 17, 2026, multiple insiders at RxSight, Inc. (NasdaqGM: RXST) stepped in to buy shares of the medical technology firm. The wave of transactions included purchases from several key individuals, showing leadership activity as the stock sits at lower levels.
Recent Insider Transactions at RxSight
A group of insiders acquired shares on June 17, 2026, in a series of open-market transactions. Julie Andrews bought 37,037 shares, while Tamara Fountain also picked up 37,037 shares on the same date. Raymond Cohen added 30,864 shares to his holdings. Additional purchases of 37,037 shares each were executed by Corley Jesse Anderson, Shweta Maniar, and William Link. None of these purchases were made under a pre-arranged Rule 10b5-1 trading plan.
RxSight Stock Trades Near Yearly Lows
RxSight shares recently changed hands around $4.73, well below the 50-day moving average of $6.09 and the 200-day moving average of $7.31. The stock has traded between a 52-week low of $4.48 and a high of $13.22. The company carries a market capitalization of roughly $213.79 million. Because the firm operates with negative earnings per share of -$1.14, it does not currently have a positive P/E ratio.
Analysts Set New Price Targets
Wall Street firms continue to track the medical device maker with a variety of ratings and price targets. On September 22, 2026, Jefferies maintained its hold rating while lowering its price target to $5.75 from $6.50. On the same day, B of A Securities kept an underperform rating and adjusted its target to $5.50. Stifel holds a hold rating with a $7.00 target, while UBS maintains a neutral stance with a $6.30 target. Needham maintains a buy rating with an $11.00 target.
Medical Technology for Cataract Surgery
Based in Aliso Viejo, California, RxSight develops and sells specialized medical devices for cataract surgery. Its main offerings include the Light Adjustable Lens and light delivery systems that allow doctors to customize patient vision post-surgery. The company employs 461 people and continues to expand its commercial reach.
What to Watch Next for RxSight
Investors will look toward the company's upcoming earnings report on November 4, 2026, to gauge revenue growth and profit margins. Market participants will also monitor any further Form 4 filings to see if leadership continues adding to their positions.
Related Filing Alerts
Source: Tammenoms Bakker Juliet's Form 4 filing on $RXST (Jun 17, 2026). Find the original filing: RXST Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts